Company News
Sun Pharma's UNLOXCYT Gets NCCN Category 2A Designation
Sun Pharma announced UNLOXCYT received NCCN Category 2A preferred designation for locally advanced cutaneous squamous cell carcinoma treatment.
The designation is based on pivotal study results showin
